Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,555.46
(
0.06%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179844

Thursday, 03/26/2015 10:11:26 AM

Thursday, March 26, 2015 10:11:26 AM

Post# of 257264
Japan approves Sovaldi/ribavirin 12-week regimen for GT2 patients:

http://finance.yahoo.com/news/japan-ministry-health-labour-welfare-060000129.html

GT1b and GT2 are the predominant HCV genotypes in Japan.

GILD submitted Harvoni for approval in Japan for GT1 patients in Sep 2014 (#msg-106569334).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today